• Targeted ablation of OX40+ T cells with engineered T cells suppresses alloreactivity and preserves antiviral immunity.

  • OX40-targeting T-cells co-expressing a tumor-specific chimeric antigen receptor protect animals from both acute GvHD and leukemia relapse.

Acute graft-versus-host disease (aGVHD) limits the therapeutic benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and requires immunosuppressive prophylaxis that compromises antitumor and antipathogen immunity. OX40 is a costimulatory receptor upregulated on circulating T cells in aGVHD and plays a central role in driving the expansion of alloreactive T cells. Here, we show that OX40 is also upregulated on T cells infiltrating GVHD target organs in a rhesus macaque model, supporting the hypothesis that targeted ablation of OX40+ T cells will mitigate GVHD pathogenesis. We thus created an OX40-specific cytotoxic receptor that, when expressed on human T cells, enables selective elimination of OX40+ T cells. Because OX40 is primarily upregulated on CD4+ T cells upon activation, engineered OX40-specific T cells mediated potent cytotoxicity against activated CD4+ T cells and suppressed alloreactive T-cell expansion in a mixed lymphocyte reaction model. OX40 targeting did not inhibit antiviral activity of memory T cells specific to Epstein-Barr virus, cytomegalovirus, and adenoviral antigens. Systemic administration of OX40-targeting T cells fully protected mice from fatal xenogeneic GVHD mediated by human peripheral blood mononuclear cells. Furthermore, combining OX40 targeting with a leukemia-specific chimeric antigen receptor in a single T cell product provides simultaneous protection against leukemia and aGVHD in a mouse xenograft model of residual disease posttransplant. These results underscore the central role of OX40+ T cells in mediating aGVHD pathogenesis and support the feasibility of a bifunctional engineered T-cell product derived from the stem cell donor to suppress both disease relapse and aGVHD following allo-HSCT.

1.
Jenq
RR
,
Van Den Brink
MRM
.
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer
.
Nat Rev Cancer
.
2010
;
10
(
3
):
213
-
221
.
2.
Granot
N
,
Storb
R
.
History of hematopoietic cell transplantation: challenges and progress
.
Haematologica
.
2020
;
105
(
12
):
2716
-
2729
.
3.
Tabbara
IA
,
Zimmerman
K
,
Morgan
C
,
Nahleh
Z
.
Allogeneic hematopoietic stem cell transplantation: complications and results
.
Arch Intern Med
.
2002
;
162
(
14
):
1558
-
1566
.
4.
Gyurkocza
B
,
Rezvani
A
,
Storb
RF
.
Allogeneic hematopoietic cell transplantation: the state of the art
.
Expert Rev Hematol
.
2010
;
3
(
3
):
285
-
299
.
5.
Cieri
N
,
Maurer
K
,
Wu
CJ
.
60 years young: the evolving role of allogeneic hematopoietic stem cell transplantation in cancer immunotherapy
.
Cancer Res
.
2021
;
81
(
17
):
4373
-
4384
.
6.
Copelan
EA
,
Chojecki
A
,
Lazarus
HM
,
Avalos
BR
.
Allogeneic hematopoietic cell transplantation; the current renaissance
.
Blood Rev
.
2019
;
34
:
34
-
44
.
7.
Sung
AD
,
Chao
NJ
.
Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment
.
Stem Cells Transl Med
.
2013
;
2
(
1
):
25
-
32
.
8.
Zeiser
R
,
Blazar
BR
.
Acute graft-versus-host disease - biologic process, prevention, and therapy
.
N Engl J Med
.
2017
;
377
(
22
):
2167
-
2179
.
9.
Nassereddine
S
,
Rafei
H
,
Elbahesh
E
,
Tabbara
I
.
Acute graft versus host disease: a comprehensive review
.
Anticancer Res
.
2017
;
37
(
4
):
1547
-
1555
.
10.
Hill
GR
,
Betts
BC
,
Tkachev
V
,
Kean
LS
,
Blazar
BR
.
Current concepts and advances in graft-versus-host disease immunology
.
Annu Rev Immunol
.
2021
;
39
:
19
-
49
.
11.
Martinez-Cibrian
N
,
Zeiser
R
,
Perez-Simon
JA
.
Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions
.
Blood Rev
.
2021
;
48
:
100792
.
12.
Hamilton
BK
.
Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation
.
Hematology
.
2018
;
2018
(
1
):
228
-
235
.
13.
Gooptu
M
,
Antin
JH
.
GVHD prophylaxis 2020
.
Front Immunol
.
2021
;
12
:
694
.
14.
Ferdjallah
A
,
Young
JAH
,
MacMillan
ML
.
A review of infections after hematopoietic cell transplantation requiring PICU care: transplant timeline is key
.
Front Pediatr
.
2021
;
9
:
755
.
15.
Weaver
CH
,
Clift
RA
,
Deeg
HJ
, et al
.
Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia
.
Bone Marrow Transplant
.
1994
;
14
(
6
):
885
-
893
.
16.
García-Cadenas
I
,
Rivera
I
,
Martino
R
, et al
.
Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease
.
Bone Marrow Transplant
.
2016
;
52
(
1
):
107
-
113
.
17.
Rubio
MT
,
Labopin
M
,
Blaise
D
, et al
.
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
.
Haematologica
.
2015
;
100
(
5
):
683
-
689
.
18.
Bacigalupo
A
,
Van Lint
MT
,
Occhini
D
, et al
.
Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia
.
Blood
.
1991
;
77
(
7
):
1423
-
1428
.
19.
Malard
F
,
Huang
XJ
,
Sim
JPY
.
Treatment and unmet needs in steroid-refractory acute graft-versus-host disease
.
Leukemia
.
2020
;
34
(
5
):
1229
-
1240
.
20.
Saad
A
,
Lamb
LS
.
Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future
.
Bone Marrow Transplant
.
2017
;
52
(
9
):
1241
-
1248
.
21.
Aversa
F
,
Pierini
A
,
Ruggeri
L
,
Martelli
MF
,
Velardi
A
.
The evolution of T cell depleted haploidentical transplantation
.
Front Immunol
.
2019
;
10
:
2769
.
22.
Nunes
NS
,
Kanakry
CG
.
Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding
.
Front Immunol
.
2019
;
10
:
2668
.
23.
Wachsmuth
LP
,
Patterson
MT
,
Eckhaus
MA
, et al
.
Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression
.
J Clin Invest
.
2019
;
129
(
6
):
2357
-
2373
.
24.
Williams
L
,
Cirrone
F
,
Cole
K
, et al
.
Post-transplantation cyclophosphamide: from HLA-haploidentical to matched-related and matched-unrelated donor blood and marrow transplantation
.
Front Immunol
.
2020
;
11
:
636
.
25.
Nagler
A
,
Kanate
AS
,
Labopin
M
, et al
.
Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia
.
Haematologica
.
2021
;
106
(
6
):
1591
-
1598
.
26.
Bolaños-Meade
J
,
Reshef
R
,
Fraser
R
, et al
.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
.
Lancet Haematol
.
2019
;
6
(
3
):
e132
-
e143
.
27.
Irene
GC
,
Albert
E
,
Anna
BV
, et al
.
Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching
.
Bone Marrow Transplant
.
2020
;
56
(
4
):
818
-
827
.
28.
Goldsmith
SR
,
Abid
MB
,
Auletta
JJ
, et al
.
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
.
Blood
.
2021
;
137
(
23
):
3291
-
3305
.
29.
Singh
A
,
Dandoy
CE
,
Chen
M
, et al
.
Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome
.
Transplant Cell Ther
.
2022
;
28
(
1
):
48.e1
-
48.e10
.
30.
Westin
JR
,
Saliba
RM
,
De Lima
M
, et al
.
Steroid-refractory acute GVHD: predictors and outcomes
.
Adv Hematol
.
2011
;
2011
.
31.
MacMillan
ML
,
Robin
M
,
Harris
AC
, et al
.
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality
.
Biol Blood Marrow Transplant
.
2015
;
21
(
4
):
761
-
767
.
32.
Axt
L
,
Naumann
A
,
Toennies
J
, et al
.
Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation
.
Bone Marrow Transplant
.
2019
;
54
(
11
):
1805
-
1814
.
33.
Zhang
Y
,
Shlomchik
WD
,
Joe
G
, et al
.
APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease
.
J Immunol
.
2002
;
169
(
12
):
7111
-
7118
.
34.
Janssen
EM
,
Lemmens
EE
,
Wolfe
T
, et al
.
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
.
Nat
.
2003
;
421
(
6925
):
852
-
856
.
35.
Ho
VT
,
Kim
HT
,
Li
S
, et al
.
Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease
.
Bone Marrow Transplant
.
2004
;
34
(
11
):
987
-
994
.
36.
Ball
LM
,
Egeler
RM
.
Acute GvHD: pathogenesis and classification
.
Bone Marrow Transplant
.
2008
;
41
(
Suppl 2
):
S58
-
S64
.
37.
Yakoub-Agha
I
,
Saule
P
,
Depil
S
, et al
.
A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy
.
Leukemia
.
2006
;
20
(
9
):
1557
-
1565
.
38.
Varlet
P
,
Alsuliman
T
,
Trauet
J
, et al
.
Donor-derived CD4+/CCR7+ T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide
.
Bone Marrow Transplant
.
2019
;
54
(
10
):
1686
-
1693
.
39.
Ni
X
,
Song
Q
,
Cassady
K
, et al
.
PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells
.
J Clin Invest
.
2017
;
127
(
5
):
1960
-
1977
.
40.
Croft
M
,
So
T
,
Duan
W
,
Soroosh
P
.
The significance of OX40 and OX40L to T cell biology and immune disease
.
Immunol Rev
.
2009
;
229
(
1
):
173
-
191
.
41.
Ukyo
N
,
Hori
T
,
Yanagita
S
,
Ishikawa
T
,
Uchiyama
T
.
Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response
.
Immunology
.
2003
;
109
(
2
):
226
-
231
.
42.
Ge
X
,
Brown
J
,
Sykes
M
,
Boussiotis
VA
.
CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors
.
Biol Blood Marrow Transplant
.
2008
;
14
(
5
):
518
-
530
.
43.
Tsukada
N
,
Akiba
H
,
Kobata
T
, et al
.
Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation
.
Blood
.
2000
;
95
(
7
):
2434
-
2439
.
44.
Tkachev
V
,
Furlan
SN
,
Watkins
B
, et al
.
Combined OX40L and mTOR blockade controls effector T cell activation while preserving T reg reconstitution after transplant
.
Sci Transl Med
.
2017
;
9
(
408
).
45.
Mo
F
,
Watanabe
N
,
McKenna
MK
, et al
.
Engineered off-the-shelf therapeutic T cells resist host immune rejection
.
Nat Biotechnol
.
2021
;
39
(
1
):
56
-
63
.
46.
Mo
F
,
Mamonkin
M
.
Generation of chimeric antigen receptor T cells using gammaretroviral vectors
.
Methods Mol Biol
.
2020
;
2086
:
119
-
130
.
47.
Cooke
KR
,
Kobzik
L
,
Martin
TR
, et al
.
An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin
.
Blood
.
1996
;
88
(
8
):
3230
-
3239
.
48.
Paz Morante
M
,
Briones
J
,
Canto
E
, et al
.
Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease
.
Clin Exp Immunol
.
2006
;
145
(
1
):
36
-
43
.
49.
Lamb
LS
,
Abhyankar
SA
,
Hazlett
L
, et al
.
Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease
.
Cytometry
.
1999
;
38
(
5
):
238
-
243
.
50.
Miller
WP
,
Srinivasan
S
,
Panoskaltsis-Mortari
A
, et al
.
GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression
.
Blood
.
2010
;
116
(
24
):
5403
-
5417
.
51.
Furlan
SN
,
Watkins
B
,
Tkachev
V
, et al
.
Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells
.
Blood
.
2016
;
128
(
21
):
2568
-
2579
.
52.
Gomes-Silva
D
,
Mukherjee
M
,
Srinivasan
M
, et al
.
Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent
.
Cell Rep
.
2017
;
21
(
1
):
17
-
26
.
53.
Kawalekar
OU
,
O’Connor
RS
,
Fraietta
JA
, et al
.
Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells
.
Immunity
.
2016
;
44
(
2
):
380
-
390
.
54.
King
MA
,
Covassin
L
,
Brehm
MA
, et al
.
Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex
.
Clin Exp Immunol
.
2009
;
157
(
1
):
104
-
118
.
55.
Ehx
G
,
Somja
J
,
Warnatz
HJ
, et al
.
Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice
.
Front Immunol
.
2018
;
9
:
1943
.
56.
Naik
S
,
Riches
M
,
Hari
P
, et al
.
Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, a CIBMTR study
.
Transpl Infect Dis
.
2019
;
21
(
5
):
e13145
.
57.
Rasche
L
,
Kapp
M
,
Einsele
H
,
Mielke
S
.
EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT
.
Bone Marrow Transplant
.
2014
;
49
(
2
):
163
-
167
.
58.
Teira
P
,
Battiwalla
M
,
Ramanathan
M
, et al
.
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
.
Blood
.
2016
;
127
(
20
):
2427
-
2438
.
59.
Fuji
S
,
Einsele
H
,
Kapp
M
.
Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options
.
Curr Opin Infect Dis
.
2017
;
30
(
4
):
372
-
376
.
60.
Zecca
M
,
Wynn
R
,
Dalle
JH
, et al
.
Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study
.
Bone Marrow Transplant
.
2019
;
54
(
10
):
1632
-
1642
.
61.
Sedláček
P
,
Petterson
T
,
Robin
M
, et al
.
Incidence of adenovirus infection in hematopoietic stem cell transplantation recipients: findings from the AdVance study
.
Biol Blood Marrow Transplant
.
2019
;
25
(
4
):
810
-
818
.
62.
Annaloro
C
,
Serpenti
F
,
Saporiti
G
, et al
.
Viral infections in HSCT: detection, monitoring, clinical management, and immunologic implications
.
Front Immunol
.
2021
;
11
:
3482
.
63.
Phelan
R
,
Arora
M
,
Chen
M
. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides.
2020
.
64.
Mavroudis
DA
,
Dermime
S
,
Molldrem
J
, et al
.
Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions
.
Br J Haematol
.
1998
;
101
(
3
):
565
-
570
.
65.
Van Dijk
AMC
,
Kessler
FL
,
Stadhouders-Keet
SAE
, et al
.
Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease
.
Br J Haematol
.
1999
;
107
(
1
):
169
-
175
.
66.
Mavroudis
DA
,
Jiang
YZ
,
Hensel
N
, et al
.
Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation
.
Bone Marrow Transplant
.
1996
;
17
(
5
):
793
-
799
.
67.
Guimond
M
,
Balassy
A
,
Barrette
M
, et al
.
P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells
.
Blood
.
2002
;
100
(
2
):
375
-
382
.
68.
Amrolia
PJ
,
Muccioli-Casadei
G
,
Yvon
E
, et al
.
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses
.
Blood
.
2003
;
102
(
6
):
2292
-
2299
.
69.
André-Schmutz
I
,
Le Deist
F
,
Hacein-Bey-Abina
S
, et al
.
Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study
.
Lancet
.
2002
;
360
(
9327
):
130
-
137
.
70.
Solomon
SR
,
Mielke
S
,
Savani
BN
, et al
.
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation
.
Blood
.
2005
;
106
(
3
):
1123
-
1129
.
71.
Mielke
S
,
McIver
ZA
,
Shenoy
A
, et al
.
Selectively T cell depleted allografts from HLA-matched sibling donors followed by low-dose post transplant immunosuppression to improve transplant outcome in patients with hematological malignancies
.
Biol Blood Marrow Transplant
.
2011
;
17
(
12
):
1855
-
1861
.
72.
Roy
DC
,
Walker
I
,
Maertens
J
, et al
.
ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia
.
Leukemia
.
2020
;
34
(
7
):
1907
-
1923
.
73.
Amrolia
PJ
,
Muccioli-Casadei
G
,
Huls
H
, et al
.
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation
.
Blood
.
2006
;
108
(
6
):
1797
-
1808
.
74.
Shrestha
B
,
Walton
K
,
Reff
J
, et al
.
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease
.
J Clin Invest
.
2020
;
130
(
9
):
4652
-
4662
.
75.
Byun
M
,
Ma Cindy
SCS
,
Akçay
A
, et al
.
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood
.
J Exp Med
.
2013
;
210
(
9
):
1743
-
1759
.
76.
Smith
M
,
Zakrzewski
J
,
James
S
,
Sadelain
M
.
Posttransplant chimeric antigen receptor therapy
.
Blood
.
2018
;
131
(
10
):
1045
-
1052
.
77.
Kochenderfer
JN
,
Dudley
ME
,
Carpenter
RO
, et al
.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
.
Blood
.
2013
;
122
(
25
):
4129
-
4139
.
78.
Brudno
JN
,
Somerville
RPT
,
Shi
V
, et al
.
Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease
.
J Clin Oncol
.
2016
;
34
(
10
):
1112
.
79.
Kebriaei
P
,
Singh
H
,
Huls
MH
, et al
.
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
.
J Clin Invest
.
2016
;
126
(
9
):
3363
-
3376
.
80.
Ghosh
A
,
Smith
M
,
James
SE
, et al
.
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
.
Nat Med
.
2017
;
23
(
2
):
242
-
249
.
81.
Sanchez
J
,
Casaño
J
,
Alvarez
MA
, et al
.
Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation
.
Br J Haematol
.
2004
;
126
(
5
):
697
-
703
.
82.
Zhang
Q
,
Lu
W
,
Liang
C-L
, et al
.
Chimeric antigen receptor (CAR) Treg: a promising approach to inducing immunological tolerance
.
Front Immunol
.
2018
;
9
:
2359
.
83.
Fransson
M
,
Piras
E
,
Burman
J
, et al
.
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
.
J Neuroinflammation
.
2012
;
9
:
112
.
84.
MacDonald
KG
,
Hoeppli
RE
,
Huang
Q
, et al
.
Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor
.
J Clin Invest
.
2016
;
126
(
4
):
1413
-
1424
.
85.
Serghides
L
,
Bukczynski
J
,
Wen
T
, et al
.
Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL
.
J Immunol
.
2005
;
175
(
10
):
6368
-
6377
.
86.
Zhao
Z
,
Condomines
M
,
van der Stegen
SJC
, et al
.
Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells
.
Cancer Cell
.
2015
;
28
(
4
):
415
-
428
.
87.
Weinkove
R
,
George
P
,
Dasyam
N
,
McLellan
AD
.
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
.
Clin Transl Immunology
.
2019
;
8
(
5
):
e1049
.
88.
Jones
BS
,
Lamb
LS
,
Goldman
F
,
Di Stasi
A
.
Improving the safety of cell therapy products by suicide gene transfer
.
Front Pharmacol
.
2014
;
5
(
November
):
1
-
8
.
You do not currently have access to this content.
Sign in via your Institution